...
asrt-img

Assertio Therapeutics Inc, Common Stock

ASRT

NAQ

$0.9621

-$0.04

(-4%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$81.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
585.95K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.73 L
$1.8 H
$0.9621

About Assertio Therapeutics Inc, Common Stock

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameASRTSectorS&P500
1-Week Return-1.58%-0.09%0.83%
1-Month Return-9.24%0.03%5.98%
3-Month Return-21.78%-6.26%9.65%
6-Month Return0.75%1.16%14.29%
1-Year Return-18.47%11.16%32.26%
3-Year Return-29.26%11.98%31.61%
5-Year Return-67.05%47.19%94.03%
10-Year Return-98.49%109.06%191.47%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue229.50M106.28M111.01M156.23M152.07M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":46.31,"profit":true},{"date":"2021-12-31","value":48.37,"profit":true},{"date":"2022-12-31","value":68.07,"profit":true},{"date":"2023-12-31","value":66.26,"profit":true}]
Cost of Revenue9.51M19.87M15.83M18.75M27.02M[{"date":"2019-12-31","value":35.18,"profit":true},{"date":"2020-12-31","value":73.55,"profit":true},{"date":"2021-12-31","value":58.59,"profit":true},{"date":"2022-12-31","value":69.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit220.00M86.40M95.18M137.49M125.05M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":39.27,"profit":true},{"date":"2021-12-31","value":43.26,"profit":true},{"date":"2022-12-31","value":62.49,"profit":true},{"date":"2023-12-31","value":56.84,"profit":true}]
Gross Margin95.86%81.30%85.74%88.00%82.23%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":84.81,"profit":true},{"date":"2021-12-31","value":89.44,"profit":true},{"date":"2022-12-31","value":91.8,"profit":true},{"date":"2023-12-31","value":85.78,"profit":true}]
Operating Expenses220.75M133.32M84.67M79.39M368.58M[{"date":"2019-12-31","value":59.89,"profit":true},{"date":"2020-12-31","value":36.17,"profit":true},{"date":"2021-12-31","value":22.97,"profit":true},{"date":"2022-12-31","value":21.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income3.20M(46.92M)9.42M57.81M(243.54M)[{"date":"2019-12-31","value":5.54,"profit":true},{"date":"2020-12-31","value":-81.15,"profit":false},{"date":"2021-12-31","value":16.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-421.24,"profit":false}]
Total Non-Operating Income/Expense(284.07M)20.72M(20.20M)(34.61M)(23.82M)[{"date":"2019-12-31","value":-1371.28,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-97.49,"profit":false},{"date":"2022-12-31","value":-167.06,"profit":false},{"date":"2023-12-31","value":-114.96,"profit":false}]
Pre-Tax Income(222.48M)(45.51M)(553.00K)31.17M(254.05M)[{"date":"2019-12-31","value":-713.87,"profit":false},{"date":"2020-12-31","value":-146.03,"profit":false},{"date":"2021-12-31","value":-1.77,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-815.16,"profit":false}]
Income Taxes(5.28M)(17.37M)728.00K(78.46M)77.89M[{"date":"2019-12-31","value":-6.78,"profit":false},{"date":"2020-12-31","value":-22.3,"profit":false},{"date":"2021-12-31","value":0.93,"profit":true},{"date":"2022-12-31","value":-100.73,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(217.20M)(28.14M)(1.28M)109.63M(331.94M)[{"date":"2019-12-31","value":-198.13,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}]
Income From Continuous Operations(217.18M)(28.14M)(1.28M)109.63M(331.94M)[{"date":"2019-12-31","value":-198.12,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(217.20M)(28.14M)(1.28M)109.63M(331.94M)[{"date":"2019-12-31","value":-198.13,"profit":false},{"date":"2020-12-31","value":-25.67,"profit":false},{"date":"2021-12-31","value":-1.17,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-302.8,"profit":false}]
EPS (Diluted)2.320.760.111.78(1.01)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":32.76,"profit":true},{"date":"2021-12-31","value":4.74,"profit":true},{"date":"2022-12-31","value":76.72,"profit":true},{"date":"2023-12-31","value":-43.53,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ASRT
Cash Ratio 0.98
Current Ratio 2.01
Quick Ratio 1.57

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ASRT
ROA (LTM) -1.44%
ROE (LTM) -42.36%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ASRT
Debt Ratio Lower is generally better. Negative is bad. 0.53
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.47

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ASRT
Trailing PE NM
Forward PE 12.48
P/S (TTM) 0.73
P/B 0.73
Price/FCF NM
EV/R 0.37
EV/Ebitda 4.03
PEG 1.25

FAQs

What is Assertio Therapeutics Inc share price today?

Assertio Therapeutics Inc (ASRT) share price today is $0.9621

Can Indians buy Assertio Therapeutics Inc shares?

Yes, Indians can buy shares of Assertio Therapeutics Inc (ASRT) on Vested. To buy Assertio Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ASRT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Assertio Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Assertio Therapeutics Inc (ASRT) via the Vested app. You can start investing in Assertio Therapeutics Inc (ASRT) with a minimum investment of $1.

How to invest in Assertio Therapeutics Inc shares from India?

You can invest in shares of Assertio Therapeutics Inc (ASRT) via Vested in three simple steps:

  • Click on Sign Up or Invest in ASRT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Assertio Therapeutics Inc shares
What is Assertio Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Assertio Therapeutics Inc (ASRT) is $1.8. The 52-week low price of Assertio Therapeutics Inc (ASRT) is $0.73.

What is Assertio Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Assertio Therapeutics Inc (ASRT) is

What is Assertio Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Assertio Therapeutics Inc (ASRT) is 0.73

What is Assertio Therapeutics Inc dividend yield?

The dividend yield of Assertio Therapeutics Inc (ASRT) is 0.00%

What is the Market Cap of Assertio Therapeutics Inc?

The market capitalization of Assertio Therapeutics Inc (ASRT) is $81.80M

What is Assertio Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Assertio Therapeutics Inc is ASRT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top